Русский
Calculation of cardiovascular risk in patients with premature ovarian insufficiency depending on its etiology
DOI: https://dx.doi.org/10.18565/therapy.2023.6.16-22
Lopukhov S.V., Nikiforov A.A., Filippov E.V.
Ryazan State Medical University of the Ministry of Healthcare of Russia
The aim was to estimate the 10-year risk of CVD calculated using the FRS and SCORE2 scales and the risk of death using the SCORE scale in patients with POI compared with a control group of healthy women.
Material and methods. The study included 399 women: 133 with primary POI, 133 with secondary POI and 133 without POI (control). The 10-year risk of CVD was assessed using the FRS and SCORE2 rating scales, and the risk of fatal complications was assessed using the SCORE scale. In determining the risk using the SCORE2 and SCORE scale, patients with CHD and diabetes mellitus were excluded from the calculation as high risk. All groups were comparable in terms of sex, age and BMI.
Results. The 10-year risk of developing CVD, both on the FRS scale and SCORE2, was statistically significantly increased in POI females comparatively with the control group. In female patients with primary POI, it was 15,1% (95% CI: 4–25,5%) on FRS and 9,4% (95% CI: 6–14%) on SCORE2 (p <0,05). In patients with secondary POI, the similar rates were 13,3% (95% CI: 3,5–25,5%) and 7,6% (95% CI:4–14%) (p <0,05). In the control group, the corresponding values were 7,2% (95% CI: 3–22,4%; p <0,05) for FRS and 5,1% (95% CI:3–14%) for SCORE2. The risk of death calculated using the SCORE scale did not differ statistically significantly in the study groups.
Conclusion. Females with POI, regardless of its etiology, had a higher burden of CVD (45 and 20% in groups with primary and secondary POI) and 10-year cardiovascular risk calculated using the FRS and SCORE2 scales. The risk of developing fatal cardiovascular events over the next 10 years, as determined by SCORE, did not statistically significantly differ between patients with various forms of POI and healthy females.
Literature
1. Марченко Л.А., Залетаев Д.В., Габибуллаева З.Г., Михайленко Д.С. Генетическая гетерогенность преждевременного истощения яичников и наследственные факторы ранней менопаузы (обзор литературы). Russian Journal of Human Reproduction. 2007; 13(1): 6–12. [Marchenko L.A., Zaletaev D.V., Gabibullaeva Z.G., Mikhalenko D.S. Genetic heterogeneity of premature ovarian exhaustion and hereditary factors of early menopause (literature review). Russian Journal of Human Reproduction. 2007; 13(1): 6–12 (In Russ.)]. EDN: LHQARN. 2. Panay N., Kalu E. Management of premature ovarian failure. Best Pract Res Clin Obstet Gynaecol. 2009; 23(1): 129–40.https://dx.doi.org/10.1016/j.bpobgyn.2008.10.008. 3. Vujovic S., Brincat M., Erel T. et al. EMAS position statement: Managing women with premature ovarian failure. Maturitas. 2010; 67(1): 91–93. https://dx.doi.org/10.1016/j.maturitas.2010.04.011. 4. Kalantaridou S.N., Naka K.K., Papanikolaou E. et al. Impaired endothelial function in young women with premature ovarian failure: Normalization with hormone therapy. J Clin Endocrinol Metab. 2004; 89(8): 3907–13. https://dx.doi.org/10.1210/jc.2004-0015. 5. Goldmeier S., De Angelis K., Rabello Casali K. et al. Cardiovascular autonomic dysfunction in primary ovarian insufficiency: Clinical and experimental evidence. Am J Transl Res. 2013; 6(1): 91–101. 6. Knauff E.A., Westerveld H.E., Goverde A.J. et al. Lipid profile of women with premature ovarian failure. Menopause. 2008; 15(5): 919–23. https://dx.doi.org/10.1097/gme.0b013e31816b4509. 7. Gulhan I., Bozkaya G., Uyar I. et al. Serum lipid levels in women with premature ovarian failure. Menopause. 2012; 19(11): 1231–34. https://dx.doi.org/10.1097/gme.0b013e318254102b. 8. Ates S., Yesil G., Sevket O. et al. Comparison of metabolic profile and abdominal fat distribution between karyotypically normal women with premature ovarian insufficiency and age matched controls. Maturitas. 2014; 79(3): 306–10.https://dx.doi.org/10.1016/j.maturitas.2014.07.008. 9. Kulaksizoglu M., Ipekci S.H., Kebapcilar L. et al. Risk factors for diabetes mellitus in women with primary ovarian insufficiency. Biol Trace Elem Res. 2013; 154(3): 313–20. https://dx.doi.org/10.1007/s12011-013-9738-0. 10. Jacobsen B.K., Knutsen S.F., Fraser G.E. Age at natural menopause and total mortality and mortality from ischemic heart disease: The Adventist Health Study. J Clin Epidemiol. 1999; 52(4): 303–7. https://dx.doi.org/10.1016/s0895-4356(98)00170-x. 11. Jacobsen B.K. Age at natural menopause and all-cause mortality: A 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol. 2003; 157(10): 923–29. https://dx.doi.org/10.1093/aje/kwg066. 12. Mondul A.M., Rodriguez C., Jacobs E.J. et al. Age at natural menopause and cause-specific mortality. Am J Epidemiol. 2005; 162(11): 1089–97. https://dx.doi.org/10.1093/aje/kwi324. 13. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–71. https://dx.doi.org/10.1016/s0140-6736(14)61682-2. 14. European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; Webber L., Davies M., Anderson R. et al. ESHRE Guideline: Management of women with premature ovarian insufficiency. Human Reproduction. 2016; 31(5): 926–37.https://dx.doi.org/10.1093/humrep/dew027. 15. Лопухов С.В., Филиппов Е.В. Анализ риска возникновения сердечно-сосудистых заболеваний и их неблагоприятных исходов, у женщин, страдающих преждевременной овариальной недостаточностью, по сравнению со здоровыми женщинами. Современные проблемы науки и образования. 2021; (4): 86. [Lopukhov S.V., Filippov E.V. Analysis of the risk of cardiovascular diseases and their adverse outcomes in women suffering from premature ovarian failure compared with healthy women. Sovremennyye problemy nauki i obrazovaniya = Modern Problems of Science and Education. 2021; (4): 86.https://dx.doi.org/10.17513/spno.31047 (In Russ.)]. EDN: WDOJEF.
About the Autors
Sergey V. Lopukhov, assistant at the Department of polyclinic therapy, preventive medicine and general medical practice, Ryazan State Medical University of the Ministry of Healthcare of Russia. Address: 390005, Ryazan, 7/1 Vysokovoltnaya Str. E-mail: LCWinor@yandex.ru.
ORCID: https://orcid.org/0000-0003-2545-7165. e-library SPIN: 8094-4549
Alexander A. Nikiforov, PhD in Medical Sciences, associate professor, associate professor of the Department of pharmacology, Ryazan State Medical University of the Ministry of Healthcare of Russia. Address: 390005, Ryazan, 7/1 Vysokovoltnaya Str. E-mail: a.nikiforov@rzgmu.ru.
ORCID: https://orcid.org/0000-0002-7364-7687. e-library SPIN: 8366-5282
Evgeny V. Filippov, MD, professor, head of the Department of polyclinic therapy, preventive medicine and general medical practice, Ryazan State Medical University of the Ministry of Healthcare of Russia. Address: 390005, Ryazan, 7/1 Vysokovoltnaya Str. E-mail: dr.philippov@vk.com.
ORCID: https://orcid.org/0000-0002-7688-7176. e-library SPIN: 2809-2781
Similar Articles
